Corcept Therapeutics Incorporated (NASDAQ: CORT)

DEFENDANT NAME: Corcept Therapeutics Incorporated
STOCK SYMBOL: NASDAQ: CORT
CASE NUMBER:
CASE NAME:
COURT:
PRACTICE AREA: Investor Fraud
STATUS: Investigation
CLASS PERIOD:
LEAD PLAINTIFF DEADLINE:
DATE FILED:
COURT LOCATION:
RELATED DOCUMENTS:
CONTACT:
510-725-3000 CORT@hbsslaw.com

Hagens Berman Sobol Shapiro LLP alerts investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) to the firm's investigation into possible securities law violations.

If you purchased or otherwise acquired securities of CORT before February 5, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more infomation contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing CORT@hbsslaw.com.

On January 25, 2019, the Southern Investigative Reporting Foundation (“SIRF”) published a report concluding Corcept is an example of what’s wrong with the healthcare system and questioned whether the Company might be using its speakers bureau program to improperly compensate doctors for prescribing its drug known as Korlym.

In response to this report, the price of Corcept shares fell $1.52, or about 11%, to close at $12.29 on January 25, 2019.

Then, on February 5, 2019, Blue Orca Capital published a report concluding Corcept’s “sole specialty pharmacy and exclusive distributor is an undisclosed related party” and, if true, the relationship “creates the material risk that the Company is using its captured pharmacy to boost sales, hide losses or engage in other financial shenanigans.”

In response, the price of Corcept shares fell as much as $1.06, or over 10%, during intraday trading on February 5, 2019.

“We’re focused on investors’ losses, the matters discussed by SIRF and Blue Orca, and whether senior management might have misled investors,” said Hagens Berman partner Reed Kathrein.

 


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Contact:

Please fill out the form below and we will get back to you as soon as we can.
 
*
*
*
*
*
*
*
*
*
*
Upload your trade data *
File Upload *
Please Explain Your Potential Legal Claim *
*
*
 

Case videos

Case Gallery

Case Timeline

02/07/19: Investigation